
TherapeuticsMD has succeeded in changing the FDA’s mind on its Imvexxy product, after an initial rejection in May of last …

Mike Elliott, Vice President of Medical Affairs at Gilead (pictured, right), chats about the company’s sponsorship of a ‘A life …

An deep learning artificial intelligence system has demonstrated its ability to outperform over 50 human dermatologists in the detection of …

Envision Pharma Group announces the successful implementation of iEnvision to connect and support Otsuka’s medical affairs activities. Otsuka Pharmaceutical Development …

It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in …

Allergan has issued a voluntary recall of its birth control medication in the US marketplace after an error in packaging …

On the day that news broke, through Pulse, that over a million patients have had to move GP surgery in …

Tim de Gavre has been announced as the new chair for the British Generic Manufacturers Association (BGMA), a position he …

A new analysis of Public Health England figures by the Local Government Association (LGA) has revealed that one in 25 …

AB Science has U-turned on its pursuit of a do-over on its marketing application of masitinib in Europe after the …

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

It’s a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an …

BioMarin is confident that its newly approved treatment for phenylketonuria (PKU) is set to become a blockbuster and it’s priced the …

AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …

The news broke at the start of the month that a number of women who should have been invited to …

Prothena Therapeutics has acted drastically by slashing staff numbers by more than half, after the failure of two pivotal trials …

The FDA has put its foot down on over-the-counter teething products for infants and children which contain benzocaine, a pain …

Pharmafocus spoke to John Crowley, CEO of Amicus Therapeutics, about his highly unusual career in the pharmaceutical and biotech industries.